Novo Nordisk A/s

Lars Skriver

Henrik Dalbo Slashedge

Hans Holmegaard So Slashedrensen

Kim Ry Hejnae Butteds

Annie Rassing Hoelgaard

Henrik Dalboge

Kim R Hejn S

A pharmaceutical preparation comprising a growth hormone and histidine or a derivative of histidine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature. Crystallization of growth hormone in the presence of histidine or a derivative thereof gives rise to a higher yield of crystals having a higher purity than known methods.

Pharmaceutical formulation

This invention is directed to isolated human AlaGlu-IGF-1, a novel compound which exerts IGF-1 activity and is a valuable precursor in the preparation of IGF-1 itself.

Human AlaGlu-IGF-1

This invention is directed to isolated DNA sequences encoding AlaGlu-IGF-1, as well as vectors and microorganisms comprising such sequences.

DNA sequences encoding AlaGlu-IGF-1 and vectors and microorganisms

Ala-Glu-IGF-I is a novel compound which exerts IGF-I activity and is a precursor for the preparation of IGF-I. Ala-Glu-IGF-I may by converted to IGF-I by renaturation after recombinant production in E. coli under specified conditions and then cleaving Ala-Glu from the IGF-I.

Growing community of inventors

Vedb.ae butted.k, Denmark

Lars Skriver